Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy
Source abstract
Abstract
Metalloimmunotherapy represents a new paradigm in cancer immunotherapy by leveraging the immune-modulatory functions of metal ions, either alone or in combination with agonists. However, the low bioavailability of free metal ions and agonists limits robust stimulation of antitumor immune responses. Here we developed multivalent metal–nucleotide nanoagonists (Mn-MNAs) through aqueous coordination of multiple nucleotide-based innate immune agonists with Fe 2+ and Mn 2+, which not only enhanced the stability and cellular uptake of the agonists but also amplified the antitumor immunity by concurrently activating the stimulator of interferon genes (STING) and toll-like receptor 9 (TLR9) pathways. Intratumoral injection of Mn-MNAs significantly inhibited tumor growth and fostered an immune-supportive tumor microenvironment in the CT26 tumor model. Intravenous administration of Mn-MNAs achieved remarkable therapeutic efficacy in the B16F10 melanoma model, which was further enhanced upon combination with a checkpoint blockade. Overall, multivalent nanoagonists open new avenues for cancer metalloimmunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Immune cells in cancer · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology
National Center for Nanoscience and Technology
School of Future Technology
University of Chinese Academy of Sciences
Foundation for Applied Molecular Evolution
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Chinese Academy of Sciences
References (59)
Show source-provided references
1. 10.1038/nature1398810.1038/nature13988 ↗
2. 10.1002/adhm.20200054910.1002/adhm.202000549 ↗
3. 10.1002/anie.20191603910.1002/anie.201916039 ↗
4. 10.1021/jacs.3c0389910.1021/jacs.3c03899 ↗
5. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
6. 10.1126/scitranslmed.abb013010.1126/scitranslmed.abb0130 ↗
7. 10.1038/s41392-024-01765-910.1038/s41392-024-01765-9 ↗
8. 10.1016/j.immuni.2023.07.01810.1016/j.immuni.2023.07.018 ↗
9. 10.1021/acs.nanolett.1c0248210.1021/acs.nanolett.1c02482 ↗
10. 10.1016/j.immuni.2014.10.01710.1016/j.immuni.2014.10.017 ↗
11. 10.1038/s41590-024-01872-310.1038/s41590-024-01872-3 ↗
12. 10.1038/nrurol.2013.15310.1038/nrurol.2013.153 ↗
13. 10.1021/acsnano.3c1137410.1021/acsnano.3c11374 ↗
14. 10.1038/s41580-020-0244-x10.1038/s41580-020-0244-x ↗
15. 10.1038/s41577-021-00524-z10.1038/s41577-021-00524-z ↗
16. 10.1021/acsnano.3c0140410.1021/acsnano.3c01404 ↗
17. 10.1038/ni102810.1038/ni1028 ↗
18. 10.1021/acs.nanolett.0c0253610.1021/acs.nanolett.0c02536 ↗
19. 10.1126/sciimmunol.abn661210.1126/sciimmunol.abn6612 ↗
20. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
21. 10.1038/s41565-022-01225-x10.1038/s41565-022-01225-x ↗
22. 10.1038/s41467-022-31238-y10.1038/s41467-022-31238-y ↗
23. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
24. 10.1021/acs.nanolett.4c0146410.1021/acs.nanolett.4c01464 ↗
25. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
26. 10.1021/jacs.4c1470010.1021/jacs.4c14700 ↗
27. 10.1021/acs.nanolett.4c0546810.1021/acs.nanolett.4c05468 ↗
28. 10.1002/anie.20181073510.1002/anie.201810735 ↗
29. 10.1039/D2NR03461A10.1039/D2NR03461A ↗
30. 10.1002/anie.20200611710.1002/anie.202006117 ↗
31. 10.1038/s41565-022-01296-w10.1038/s41565-022-01296-w ↗
32. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
33. 10.1002/anie.20230727210.1002/anie.202307272 ↗
34. 10.1002/adma.20230484510.1002/adma.202304845 ↗
35. 10.1002/adma.20240405310.1002/adma.202404053 ↗
36. 10.1002/anie.20190341710.1002/anie.201903417 ↗
37. 10.1126/sciadv.adf332910.1126/sciadv.adf3329 ↗
38. 10.1126/sciadv.aaz610810.1126/sciadv.aaz6108 ↗
39. 10.1021/acssuschemeng.9b0322410.1021/acssuschemeng.9b03224 ↗
40. 10.1021/la902583j10.1021/la902583j ↗
41. 10.1016/S0301-4622(03)00035-810.1016/S0301-4622(03)00035-8 ↗
42. 10.1002/smll.20210712310.1002/smll.202107123 ↗
43. 10.1016/j.apsusc.2020.14543610.1016/j.apsusc.2020.145436 ↗
44. 10.1126/science.123726510.1126/science.1237265 ↗
45. 10.1002/anie.20131113610.1002/anie.201311136 ↗
46. 10.1002/anie.20210174410.1002/anie.202101744 ↗
47. 10.1016/j.celrep.2023.11218510.1016/j.celrep.2023.112185 ↗
48. 10.1016/j.immuni.2011.02.02210.1016/j.immuni.2011.02.022 ↗
49. 10.1038/s41577-018-0117-010.1038/s41577-018-0117-0 ↗
50. 10.1073/pnas.210022511810.1073/pnas.2100225118 ↗
51. 10.1016/j.celrep.2017.10.05410.1016/j.celrep.2017.10.054 ↗
52. 10.1016/j.celrep.2022.11098910.1016/j.celrep.2022.110989 ↗
53. 10.1016/j.immuni.2006.08.00910.1016/j.immuni.2006.08.009 ↗
54. 10.1038/nri124610.1038/nri1246 ↗
55. 10.1038/ni111210.1038/ni1112 ↗
56. 10.1021/acscentsci.3c0131010.1021/acscentsci.3c01310 ↗
57. 10.1038/s43018-024-00889-910.1038/s43018-024-00889-9 ↗
58. 10.1038/s41551-022-00888-010.1038/s41551-022-00888-0 ↗
59. 10.1038/s41586-025-09249-810.1038/s41586-025-09249-8 ↗